Tinnen Quoted in Reorg About Termination Fees in Alexion Pharmaceuticals Proposed Acquisition of Portola Pharmaceuticals

12 May 2020 Reorg News

Partner Clyde Tinnen was quoted in the Reorg article, “Past Alexion Guidance Bodes Well for Quick Review,” about Alexion’s planned acquisition of Portola in 2020. Although the deal is expected to withstand regulatory scrutiny, Portola would owe Alexion a termination fee in certain circumstances. “All things being equal, break up fees typically do provide a strong protective device for buyers to keep sellers in a deal,” Tinnen said.

(Subscription required)

Related Services

Insights

DOL Rolls Back Trump Administration’s Independent Contractor Rule
05 May 2021
Labor & Employment Law Perspectives
190 Across the Finish Line: CFTC Adopts New Bankruptcy Rules for FCMS and DCOS
05 May 2021
The Journal on the Law of Investment & Risk Management Products, Futures & Derivatives Law Report
Understanding SPACs' Hidden Capital Costs
05 May 2021
Law360
The Export Import Bank of the United States: Priorities and Programs Supporting U.S. Businesses and Jobs
04 May 2021
Manufacturing Industry Advisor
Home Care 100
27-30 June 2021
Marco Island, FL
2021 AANP National Conference
15 June - 31 August 2021
Virtual Conference
HCCA Orange County Regional Healthcare Compliance Conference
11 June 2021
Virtual Conference
Rx Pricing and Reimbursement Summit
24-25 May 2021
Virtual Conference